Immigration Ban: BioPharma Response Varies From Silence To Dissent
Executive Summary
While PhRMA, BIO and Pfizer had no response to President Trump’s travel order, Allergan and some smaller firms voiced their objections; PhRMA to meet with Trump on Tuesday.
You may also be interested in...
PhRMA And Trump: 'Go Boldly,' Or Tread Carefully?
Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?
Biotech Execs Speak Out Against Trump’s Immigration Ban; Big Pharma Remains Mostly Silent
Letter initiated by six CEOs drew 'absolutely overwhelming' response as 163 leaders of primarily small biotech and venture capital firms signed on; tech firms join court fight.
Biotech Execs Speak Out Against Trump’s Immigration Ban; Big Pharma Remains Mostly Silent
Letter initiated by six CEOs drew 'absolutely overwhelming' response as 163 leaders of primarily small biotech and venture capital firms signed on; tech firms join court fight.